Who Is More Likely to Have Side Effects From GLP-1 Medications?

First: What Side Effects Are Most Common?

The most common GLP-1-related side effects involve the gastrointestinal system and include:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Abdominal discomfort

• Indigestion or reflux

• Bloating

• Feeling unusually full

• Decreased appetite

A 2026 review in the Journal of Clinical Investigation reported that randomized trials consistently show increased risks of nausea, vomiting, diarrhea, and constipation with GLP-1-based medications compared with placebo.

However, these symptoms are not required for the medication to work.

In the SURPASS tirzepatide trials, weight loss was substantial in participants both with and without nausea, vomiting, or diarrhea, and less than 6% of the treatment's weight-loss effect was attributable to these GI symptoms.

Feeling sick does not mean the medication is working better.

Learn More About Side Effects Here

So Who May Be More Likely to Experience GI Side Effects?

1. People Who Already Have Gastrointestinal Problems

This may be one of the strongest patient-specific signals identified so far.

A 2024 real-world study evaluated 855 adults with type 2 diabetes starting GLP-1 receptor agonists. A previous history of gastrointestinal disorders was one of the strongest predictors of developing GI side effects.

After accounting for other factors, patients with a history of GI disorders had approximately six times the odds of developing GI side effects compared with patients without that history.

A separate 2025 study specifically examining semaglutide in 215 patients with type 2 diabetes also identified concurrent gastrointestinal disorders as an independent risk factor for semaglutide-related GI adverse events.

This might include people who already struggle with symptoms such as:

• Chronic nausea

• Significant reflux

• Chronic constipation

• Persistent bloating

• Early fullness

• Abnormal gastric motility

• Other significant gastrointestinal disorders

This does not automatically mean someone cannot use a GLP-1 medication.

It does mean that their baseline symptoms matter.

If you already have significant GI symptoms before starting treatment, your provider needs to know what is normal for you so new or worsening symptoms can be recognized.

2. People Who Are Increasing Their Dose

The period immediately after starting treatment or increasing the dose is one of the most consistent risk periods for GI symptoms.

In pooled STEP 1–3 obesity trials involving more than 2,100 participants receiving semaglutide 2.4 mg, nausea, diarrhea, vomiting, and constipation occurred more frequently with semaglutide than placebo.

Importantly, symptoms occurred most frequently during or shortly after dose escalation.

The same pattern appears with tirzepatide.

Across the SURMOUNT 1–4 trials, GI adverse events were concentrated primarily during dose escalation and were usually mild to moderate.

This is one reason GLP-1 medications are titrated gradually rather than started at a maintenance dose.

Faster is not necessarily better.

The 2026 JCI review notes that more aggressive dose escalation may produce additional treatment effect, but it can come at the expense of greater adverse effects. The authors specifically suggest that more individualized dose-escalation strategies may improve tolerability.

A patient who is responding well does not necessarily need to race to the highest available dose.

3. Older Adults May Be More Susceptible

Age has emerged as a possible predictor in several real-world studies.

In the 855-patient GLP-1 study, increasing age independently predicted gastrointestinal side effects. Each additional year of age was associated with approximately a 5% increase in the odds of developing GI symptoms within that study population.

Pharmacovigilance studies have also identified age as a factor associated with GI adverse-event severity or reporting.

However, this finding needs some perspective.

Clinical trials have not consistently shown dramatically higher GI adverse-event rates solely because someone is older. The JCI review also notes that higher discontinuation among adults 65 and older may reflect a combination of tolerability, cost, effectiveness, comorbidity, and patient preference.

For older adults, the consequences of significant appetite suppression may also matter more.

Providers may need to watch more closely for:

• Dehydration

• Inadequate calorie intake

• Inadequate protein intake

• Loss of muscle mass

• Frailty

• Dizziness or orthostasis

• Constipation

So age does not mean "you shouldn't take a GLP-1."

It may mean titration and nutrition deserve more attention.

4. Women May Have a Higher Risk in Some Studies

This is an area where newer data are becoming interesting.

In the 2024 study of 855 adults with type 2 diabetes, female sex was associated with approximately 2.3 times the odds of developing GLP-1-related GI side effects after adjustment for other factors.

However, this finding has not been completely consistent across studies.

For example, a large semaglutide pharmacovigilance analysis found age and body weight were related to severity of reported GI events, while sex was not significantly associated with severity.

And a 2026 pharmacovigilance analysis of tirzepatide actually found higher GI adverse-event reporting in males.

So I would not tell a patient:

"Women are definitely more likely to get sick on GLP-1s."

The better interpretation is:

Sex may influence susceptibility, but the research is inconsistent and we do not yet understand the relationship well enough to use sex alone to predict tolerability.

5. People Taking Several Other Oral Medications

Polypharmacy may matter.

In the 855-patient study, the number of other oral medications being taken was independently associated with GLP-1 gastrointestinal side effects. Each additional oral medication was associated with higher odds of GI intolerance within that population.

There are several possible explanations.

Some medications independently cause:

• Nausea

• Diarrhea

• Constipation

• Reflux

• Delayed gastric emptying

• Reduced appetite

The more medications someone is taking, the more difficult it can also become to determine which medication is producing which symptom.

This is one reason medication reconciliation matters before starting treatment.

6. Certain Diabetes Medications May Add to GI Symptoms

Some diabetes medications already cause gastrointestinal symptoms.

A 2025 semaglutide study found that simultaneous use of alpha-glucosidase inhibitors was independently associated with semaglutide-related GI adverse events.

Other research has also raised the possibility that medications such as metformin may contribute to the overall GI symptom burden in some patients, although the relationship is not consistent enough to label metformin itself a universal GLP-1 intolerance risk factor.

The practical point is simple:

Your whole medication list matters, not just your GLP-1.

7. Alcohol Use May Matter

A 2025 study examining semaglutide-related GI adverse events in people with type 2 diabetes identified alcohol consumption as an independent risk factor.

That finding is interesting but should not be overgeneralized.

It was one relatively small study and does not establish that alcohol will cause GLP-1 intolerance in everyone.

Alcohol itself can irritate the stomach, worsen reflux, contribute to nausea, and increase dehydration. Someone already experiencing medication-related nausea or vomiting may therefore tolerate alcohol poorly.

8. People With Diabetes May Have More Baseline GI Vulnerability

Diabetes itself can affect gastrointestinal function.

Long-standing diabetes may contribute to autonomic nerve dysfunction and altered gastric or intestinal motility. Some people with diabetes already experience nausea, constipation, diarrhea, early satiety, or abnormal gastric emptying before ever taking a GLP-1 medication.

The JCI review emphasizes an important point: gastrointestinal symptoms are already more common among people with diabetes even when they are not taking a GLP-1 medication.

A 2026 tirzepatide pharmacovigilance analysis also found higher reporting of gastrointestinal adverse events among patients with type 2 diabetes compared with those using tirzepatide for weight management.

That means baseline symptoms should be documented whenever possible.

Otherwise, every stomach complaint that happens after starting treatment can easily be blamed on the medication.

What About BMI?

This one is surprisingly unclear.

You may hear that people with a lower BMI are more likely to experience GLP-1 side effects.

Current research does not establish this reliably.

In the 855-patient GLP-1 study, BMI initially appeared different between people with and without GI symptoms, but BMI was no longer a statistically significant independent predictor after other factors were considered.

A pharmacovigilance analysis of semaglutide did find an association between body weight and severity of reported GI events, but pharmacovigilance databases cannot determine individual risk the same way a prospective clinical trial can.

For now, BMI alone is not a good way to predict who will tolerate treatment.

What About Kidney Disease?

Kidney disease does not necessarily make someone unable to use a GLP-1 medication, and these medications may provide important cardiovascular and kidney benefits in appropriately selected patients.

The greater concern is what happens if significant vomiting or diarrhea occurs.

GI losses can cause:

• Dehydration

• Low blood pressure

• Electrolyte abnormalities

• Worsening kidney function

• Acute kidney injury

FDA review documents for tirzepatide describe cases in which gastrointestinal adverse events contributed to volume depletion, dehydration, electrolyte abnormalities, hypotension, and acute kidney injury.

Someone with reduced kidney reserve may therefore have less room for prolonged dehydration than someone with normal renal function.

Why Do GLP-1 Medications Cause Nausea Anyway?

It is tempting to say:

"GLP-1 medications cause nausea because they slow the stomach."

That is only part of the story.

GLP-1 receptor agonists do slow gastric emptying and suppress intestinal motility.

But they also affect the brain.

GLP-1 receptors are present in brainstem regions involved in nausea and vomiting, particularly the:

• Area postrema

• Nucleus tractus solitarius

GLP-1 signals may also reach these areas through the vagus nerve.

This matters because research suggests that:

slowing gastric emptying, reducing food intake, and producing nausea are related effects, but they are not exactly the same biological pathway.

That helps explain why one patient can have excellent appetite control with no nausea while another feels miserable.

Learn More about how GLP-1 cause nausea HERE

How Long Do GI Side Effects Usually Last?

They are often most noticeable early in treatment.

In the pooled STEP obesity trials with semaglutide:

• Median nausea episodes lasted about 8 days

• Diarrhea about 3 days

• Vomiting about 2 days

Constipation tended to last considerably longer, with a median duration around 47 days among participants receiving semaglutide.

Most nausea, vomiting, and diarrhea decreased after the dose-escalation period.

That does not mean severe or persistent symptoms should simply be endured.

Does More Nausea Mean More Weight Loss?

No.

This is worth repeating because it is one of the biggest misconceptions about GLP-1 therapy.

Across the SURPASS tirzepatide trials, participants lost substantial weight whether or not they experienced nausea, vomiting, or diarrhea. Less than 6% of the difference in weight loss was attributed to GI adverse effects.

The same general pattern was seen in SURMOUNT obesity trials, where nausea, vomiting, diarrhea, and dyspepsia accounted for only a small proportion of total weight reduction.

Nausea is an adverse effect, not a therapeutic target.

Sometimes the Problem Is Too Much Appetite Suppression

Not all excessive GLP-1 effects look like vomiting.

Sometimes a patient says:

"I'm never hungry."

That may sound desirable during weight-loss treatment, but complete appetite suppression is not necessarily the goal.

If you regularly cannot consume enough:

• Protein

• Fluids

• Calories

• Micronutrients

your treatment may need to be reassessed.

Weight loss should primarily target excess adipose tissue while preserving as much lean mass, strength, function, and nutritional health as possible.

The correct dose is not automatically the dose that makes eating hardest.

Rapid Weight Loss Has Its Own Risks

Another issue can occur even when the medication itself feels perfectly tolerable.

GLP-1 treatment has been associated with an increased risk of gallstones.

The 2026 JCI review cites randomized trial data showing an approximately 46% relative increase in cholelithiasis compared with placebo.

Rapid and substantial weight loss itself is also a known contributor to gallstone formation.

So an aggressive rate of weight loss is not automatically better.

Who Might Need a More Conservative Approach?

Based on current evidence, it may be reasonable for providers to pay additional attention to patients who have:

• A history of significant gastrointestinal symptoms or GI disease

• Difficulty tolerating a previous GLP-1 medication

• Symptoms that repeatedly appear after dose increases

• Older age or frailty

• Multiple medications that can affect the GI tract

• Diabetes with possible autonomic or gastric motility problems

• Kidney disease or increased vulnerability to dehydration

• Difficulty maintaining adequate hydration or nutrition

Some research also suggests possible associations with sex, alcohol use, and specific concomitant medications, but these findings need further confirmation before they can be considered universal predictors.

What Can We Actually Do With This Information?

The goal is not to label patients as "good" or "bad" GLP-1 candidates based on one risk factor.

Instead, this information can help individualize treatment.

For someone who appears more susceptible to GI effects, a clinician may consider strategies such as:

• Allowing more time at a tolerated dose before increasing

• Avoiding dose escalation while significant symptoms are present

• Reviewing other medications that may contribute to GI symptoms

• Addressing constipation proactively

• Monitoring hydration and nutrition

• Using smaller meals

• Reducing very high-fat meals if they provoke symptoms

• Reassessing the dose if appetite suppression becomes excessive

The prescribing information provides a titration schedule, but individual tolerability still matters.

When Should You Contact Your Provider?

Mild nausea, fullness, constipation, diarrhea, or decreased appetite can occur during treatment, particularly when starting or increasing the dose.

Contact your healthcare provider if symptoms are:

• Persistent

• Worsening

• Difficult to manage

• Interfering with normal eating or drinking

• Causing repeated vomiting

• Causing significant constipation or abdominal discomfort

Seek prompt medical evaluation for symptoms such as:

• Severe or persistent abdominal pain

• Repeated vomiting

• Inability to keep fluids down

• Signs of significant dehydration

• Fainting or significant weakness

• Severe abdominal distension

• Blood in vomit or stool

• Other severe or rapidly worsening symptoms

The Bottom Line

We are getting better at understanding who may be more vulnerable to GLP-1 side effects, but there is still no validated test that can predict exactly how an individual patient will respond.

The strongest emerging signals include:

• Pre-existing gastrointestinal problems

• Dose escalation

• Older age in some populations

• Taking multiple oral medications

• Certain medications that already cause GI symptoms

Sex, alcohol exposure, diabetes status, and other factors may also influence tolerability, but the evidence is less consistent.

Most importantly, GLP-1 treatment does not need to be miserable to be effective.

You do not need nausea to lose weight. You do not need to eliminate hunger completely. And you do not need to reach the highest available dose simply because it exists.

The goal is to find the dose and treatment strategy that provides meaningful benefit while remaining tolerable, nutritionally appropriate, and sustainable long term.

References

Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026;136(4):e194740. doi:10.1172/JCI194740.
JCI full text | PubMed

Gao R, Li Y, Li A, et al. Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs. Front Endocrinol (Lausanne). 2024;15:1502050. doi:10.3389/fendo.2024.1502050.
Full text | PubMed

Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus. Front Endocrinol. 2025.
PubMed

Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551.
Free full text PMC | PubMed

Patel H, Khunti K, Rodbard HW, et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024;26(2):473-481. doi:10.1111/dom.15333.
PubMed

Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27(4):1826-1835. doi:10.1111/dom.16176.
Free full text PMC | PubMed

Shen P, Peng MS, Kim SJ, Joung KI, Kim KJ. Gastrointestinal adverse events associated with tirzepatide: a bibliometric and pharmacovigilance analysis. PLoS One. 2026;21(3):e0344289. doi:10.1371/journal.pone.0344289.
PLOS full text | PubMed

Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi:10.3389/fpubh.2022.996179.
Full text | PubMed

Medical Disclaimer: This information is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. GLP-1 medications are prescription medications and may not be appropriate for everyone. Medication selection, dosing, dose escalation, and treatment of side effects should be individualized by a qualified healthcare professional based on medical history, current medications, treatment response, and individual risks.

Ready to Start Your Weight Management Journey?

GLP-1 medications can be powerful tools, but the right medication, dose, and rate of dose escalation can be different for each person.

At Optima Vida Healthcare, weight management is individualized based on your health history, previous treatments, response to medication, side effects, goals, and long-term needs.

Treatment may include GLP-1 or other weight-management medications when medically appropriate, along with ongoing monitoring and support.

Start Your Weight Management Evaluation →

Or Visit www.ovhmed.com for more information.

Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare provider.

Contact

Optima Vida Healthcare, LLC
Telehealth medical services
support@ovhmed.com

© 2026 Optima Vida Healthcare, LLC. All rights reserved.

Privacy Policy | Notice of Privacy Practices | Terms of Use | Telehealth Information | Recurring Payment Policy